Economic evaluation of biological treatments in patients with severe asthma: a systematic review

References

• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9
   PubMed Web of Science ®Google Scholar
• Reddel H, Bacharier L, Bateman E, et al. Pocket Guide for Asthma Management: for Adults and Children over 5 years. GINA US; 2020.
   Google Scholar
• Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008–2013. Ann Am Thoracic Soc. 2018;15(3):348–356.
   PubMed Web of Science ®Google Scholar
• Vellopoulou K, Bakakos P, Loukides S, et al. The economic burden of asthma in Greece: a cross-sectional Study. Appl Health Econ Health Policy. 2019;17(5):629–640.
   PubMed Web of Science ®Google Scholar
• Vogler S, Dedet G, Pedersen HB. Financial burden of prescribed medicines included in outpatient benefits package schemes: comparative analysis of co-payments for reimbursable medicines in European countries. Appl Health Econ Health Pol. 2019;17(6):803–816.
   PubMed Web of Science ®Google Scholar
• Accordini S, Corsico AG, Braggion M, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol. 2013;160(1):93–101. doi:10.1159/000338998
   PubMed Web of Science ®Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res and Pract. 2017;3(1):1–11.
   PubMedGoogle Scholar
• Basu A, Dalal A, Canonica GW, et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):121–131. doi:10.1080/14737167.2017.1298444
   PubMed Web of Science ®Google Scholar
• Price D, Fletcher M, Van Der Molen T. Asthma control and management in 8,000 European patients: the Recognise Asthma and LInk to Symptoms and Experience (REALISE) survey. Npj Prim Care Resp Med. 2014;24(1):1–10.
   Google Scholar
• Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111(6):1212–1218. doi:10.1067/mai.2003.1449
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost effectiveness of pharmacological treatments for asthma: a systematic review. Pharmacoeconomics. 2018;36(10):1165–1200.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• McCracken J, Tripple J, Calhoun WJ. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immunol. 2016;16(4):375.
   PubMed Web of Science ®Google Scholar
• Menzella F, Galeone C, Ghidoni G, et al. The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review. Multidiscip Respir Med. 2021;16(1):787. doi:10.4081/mrm.2021.787
   PubMedGoogle Scholar
• Domínguez-Ortega J, Phillips-Anglés E, Barranco P, et al. Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma. 2015;52(6):529–537.
   PubMed Web of Science ®Google Scholar
• Andersson M, Janson C, Kristensen T, et al. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid–dependent asthma in Sweden. J Med Econ. 2020;23(8):877–884.
   PubMed Web of Science ®Google Scholar
• Kallieri M, Zervas E, Katsoulis K, et al. Mepolizumab in severe eosinophilic asthma: a 2-year follow-up in specialized asthma clinics in Greece: an interim analysis. Int Arch Allergy Immunol. 2020;181(8):613–617. doi:10.1159/000508559
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-2018
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Virchow JC, Murphy K, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2020;8(5):461–474. doi:10.1016/S2213-2600(19)30372-8
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(jul21 1):b2700–b2700. doi:10.1136/bmj.b2700
   PubMed Web of Science ®Google Scholar
• Dotoli M, Epicoco N, Falagario M Integrated supplier selection and order allocation under uncertainty in agile supply chains. In: Proceedings of 2015 Ieee 20th Conference on Emerging Technologies & Factory Automation. (IEEE, Luxembourg, 2015)
   Google Scholar
• Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010;19(3):350–364.
   PubMed Web of Science ®Google Scholar
• Evers S, Goossens M, De Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240–245.
   PubMed Web of Science ®Google Scholar
• McCabe C, Paulden M, Awotwe I, et al. One-way sensitivity analysis for probabilistic cost-effectiveness analysis: conditional expected incremental net benefit. Pharmacoeconomics. 2020;38(2):135–141.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Colombo GL, Rogliani P, et al. omalizumab for severe allergic asthma treatment in Italy: a cost-effectiveness analysis from PROXIMA study. RMHP. 2020;13:43–53.
   Google Scholar
• Han S, Kim S, Kim H, et al. Cost–utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea. Curr Med Res Opin. 2019;35(9):1597–1605.
   PubMed Web of Science ®Google Scholar
• Lam J, Hay JW, Salcedo J, et al. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2019;56(8):872–881.
   PubMed Web of Science ®Google Scholar
• Tadrous M, Khuu W, Lebovic G, et al. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Ann Allergy Asthma Immunol. 2018;120(1):59–65. doi:10.1016/j.anai.2017.08.016
   PubMed Web of Science ®Google Scholar
• Chaplin S. Diagnosis, monitoring and management of chronic asthma. Prescriber. 2018;29(4):31–33.
   Google Scholar
• Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis. 2012;6(2):87–95. doi:10.1177/1753465811429478
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Campbell JD, Ghushchyan VH, et al. Outcomes before and after treatment escalation to global initiative for asthma steps 4 and 5 in severe asthma. Ann Allergy Asthma Immunol. 2015;114(6):462–469.10.1016/j.anai.2015.03.019
   PubMed Web of Science ®Google Scholar
• Zhou H, Lu Y, Wu B, et al. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. J Asthma. 2020;57(1):87–94.
   PubMed Web of Science ®Google Scholar
• Pamuk G, Le Bourgeois M, Abou Taam R, et al. The economic burden of severe asthma in children: a comprehensive study. J Asthma. 2021;58(11):1467–1477.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Iwata M, Matsuzaki H, et al. Impact of omalizumab on medical cost of childhood asthma in Japan. Pediatr Int. 2016;58(5):425–428. doi:10.1111/ped.12936
   PubMed Web of Science ®Google Scholar
• Chung Y, Katial R, Mu F, et al. Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022;128(6):669–676.e6. doi:10.1016/j.anai.2022.02.017
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Li Q, Bilir SP, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23–32. doi:10.1080/03007995.2019.1660539
   PubMed Web of Science ®Google Scholar
• Suzuki C, Lopes da Silva N, Kumar P, et al. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832–839.
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765–1776.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy. 2010;65(9):1141–1148.
   PubMed Web of Science ®Google Scholar
• Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value Health. 2014;17(8):772–782.
   PubMed Web of Science ®Google Scholar
• González-Barcala FJ, Muñoz-Gall X, Mariscal E, et al. Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain. J Med Econ. 2021;24(1):874–882. doi:10.1080/13696998.2021.1941065
   PubMed Web of Science ®Google Scholar
• Brown R, Turk F, Dale P, et al. Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007;62(2):149–153.
   PubMed Web of Science ®Google Scholar
• Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114(2):265–269.
   PubMed Web of Science ®Google Scholar
• Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J Allergy Clin Immunol. 2007;120(5):1146–1152.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Sadatsafavi M, Mark FitzGerald J. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Allocation. 2018;16(1):1–8.
   PubMedGoogle Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225. doi:10.1016/j.anai.2016.10.028
   PubMed Web of Science ®Google Scholar
• Jefferson Antonio B, Patiño DG, Lopez Moreno M. Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2022;22(2):299–305.
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, García-Ruiz AJ, Levy Abitbol RC, et al. Real-life cost-effectiveness of benralizumab in patients with severe asthma. Respir Res. 2021;22(1):163. doi:10.1186/s12931-021-01758-0
   PubMed Web of Science ®Google Scholar
• Tan LE, Tan WHG, Aziz MIA, et al. Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore. J Asthma. 2022;59(1):189–199. doi:10.1080/02770903.2020.1837158
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012;49(8):843–848.
   PubMed Web of Science ®Google Scholar
• Jahnz-Różyk K, Lis J, Warchoł M, et al. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. BMC Pulm Med. 2018;18(1):1–9.
   PubMedGoogle Scholar
• Levy AN, García a Ruiz AJ, García-Agua Soler N, et al. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–210.
   PubMed Web of Science ®Google Scholar
• Vennera M, Valero A, Uría E, et al. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–578.
   PubMed Web of Science ®Google Scholar
• Ortega H, Hahn B, Bogart M, et al. Impact of mepolizumab on exacerbations in severe asthma: results from a US insurance claims data base. Allergy Asthma Proc. 2020;41(5):341–347. doi:10.2500/aap.2020.41.200043
   Web of Science ®Google Scholar
• Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG, et al. Economic impact and clinical outcomes of omalizumab add-on therapy for patients with severe persistent asthma: a real-world study. PharmacoEconomics Open. 2019;3(3):333–342. doi:10.1007/s41669-019-0117-4
   PubMed Web of Science ®Google Scholar
• Martínez-Moragón E, Climent M, Chiner E, et al. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice. Farmacia Hospitalaria. 2019;43(3):101–109.
   PubMed Web of Science ®Google Scholar
• Verhamme KMC, Lucet C, Van Meerhaeghe A, et al. Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. ERJ Open Res. 2019;5(4):00253–2018.
   PubMedGoogle Scholar
• Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29–36.
   PubMedGoogle Scholar
• Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci. 2011;180(3):637–641.
   PubMed Web of Science ®Google Scholar
• Llanos J-P, Bell CF, Packnett E, et al. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study. J Asthma Allergy. 2019;12:43–43.
   PubMed Web of Science ®Google Scholar
• Llanos J-P, Ortega H, Bogart M, et al. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;13:77–77.
   PubMed Web of Science ®Google Scholar
• García-Mochón L, Gil-Sierra M-D, Alegre-Del Rey E-J, et al. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma. Farmacia Hospitalaria. 2019;43(6):187–193.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford University Press. 2016. doi:10.1093/acprof:oso/9780190492939.001.0001
   Google Scholar
• Beaulieu E, DiGennaro C, Stringfellow E, et al. Economic evaluation in opioid modeling: systematic review. Value Health. 2021;24(2):158–173. doi:10.1016/j.jval.2020.07.013
   PubMed Web of Science ®Google Scholar
• Byford S, Raftery J. Economics notes: perspectives in economic evaluation. BMJ. 1998;316(7143):1529–1530.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Pauly MV, Willke RJ, et al. An overview of value, perspective, and decision context—a health economics approach: an ISPOR special task force report [2]. Value Health. 2018;21(2):124–130.
   PubMed Web of Science ®Google Scholar
• Shields GE, Elvidge J. Challenges in synthesising cost-effectiveness estimates. Syst Rev. 2020;9:289. doi:10.1186/s13643-020-01536-x
   Google Scholar